Jefferies Raises Price Target on Bristol-Myers Squibb (BMY) Following 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
AstraZeneca (AZN) Shares Decline After Recruitment Paused in Head and Neck Cancer Trial
October 27, 2016 10:58 AM EDT(Updated - October 27, 2016 11:44 AM EDT)
(Updated - October 27, 2016 11:13 and 11:27 AM EDT)
AstraZeneca (NYSE: AZN) declined Thursday, falling over 4% intraday. Chatter suggested weakness was related to a halt in recruitment for its trial evaluating its IO combo in head and neck... More
Stocks dip as earnings pour in, consumer discretionary lags
October 27, 2016 7:34 AM EDTBy Chuck Mikolajczak
NEW YORK (Reuters) - U.S. stocks dipped in a choppy session after the latest round of earnings reports, as a decline in the consumer discretionary sector and interest-rate sensitive stocks outweighed gains in healthcare names.
The S&P 500 healthcare index rose 0.53 percent to help keep the S&P 500 near the unchanged mark, buoyed by strong results and forecasts from Bristol-Myers (NYSE: BMY), up 5.4 percent and Celgene (NASDAQ: CELG), up 6.4 percent. The two drugmakers were the top boosts to the S&P 500.
... MoreBristol-Myers Squibb (BMY) Tops Q3 EPS by 12c; Boosts FY16 Outlook; Approves New $3B Stock Buyback Plan
October 27, 2016 7:00 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q3 EPS of $0.77, $0.12 better than the analyst estimate of $0.65. Revenue for the quarter came in at $4.83 billion versus the consensus estimate of $4.79 billion.
Bristol-Myers Squibb today announced its Board of Directors approved a new $3 billion repurchase... More
Stocks with Implied Volatility Movement
October 27, 2016 5:21 AM EDTBristol-Myers Squibb (NYSE: BMY) implied volatility at upper end of index mean range
... MoreTrading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
October 26, 2016 2:46 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
Acorda Therapeutics (Nasdaq: ACOR) - no Street consensus
Aetna (NYSE: AET) - consensus EPS $2.03
Agenus (Nasdaq: AGEN) - consensus loss $0.29
Air Products (NYSE:... More
